| gefitinib vs | No demonstrated result suggested progression or death (progression free survival PFS) by 96% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 1.96 [1.38 2.79] | p=0.04 | 0 | -18 | 1 | CTONG0806 (Yang), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| gefitinib vs carboplatin-paclitaxel | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| gefitinib vs carboplatin/paclitaxel | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| gefitinib vs cisplatin plus docetaxel | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| gefitinib vs continued platinum-doublet chemotherapy | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| gefitinib vs docetaxel | No demonstrated result suggested objective response (ORR) by 49% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | 1.49 [1.17 1.91] | p=0.04 | 0 | -72 | 4 | ISTANA (Lee),V-15-32 (Maruyama),INTEREST (Kim),SIGN (Cufer), | | death (overall survival) | 1.02 [0.92 1.12] | p=1.00 | 0 | -72 | 4 | ISTANA (Lee),V-15-32 (Maruyama),INTEREST (Kim),SIGN (Cufer), | | progression or death (progression free survival PFS) | 0.97 [0.88 1.07] | p=1.00 | 0 | -72 | 4 | ISTANA (Lee),V-15-32 (Maruyama),INTEREST (Kim),SIGN (Cufer), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| gefitinib vs gefitinib | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| gefitinib vs gemcitabine and cisplatin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| gefitinib vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| gefitinib vs vinorelbine | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| gefitinib paclitaxel and carboplatin vs paclitaxel and carboplatin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| gefitinib + gemcitabine/cisplatin vs placebo + gemcitabine / cisplatin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| objective response (ORR) | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
